Antimycotic activity of green tea phytocompounds against Candida glabrata
##plugins.themes.bootstrap3.article.main##
##plugins.themes.bootstrap3.article.sidebar##
https://orcid.org/0000-0002-3269-1403
Manjusha Tyagi Rakesh Kuamar Bachheti Ashish Thapliyal Nishant Rai
Abstract
One of the medically important opportunistic fungal pathogen for humans is Candida glabrata that causes various types of candidiasis. Its environmental adaptations and antimicrobial resistance is now a great concern for public health. In the present study, the green tea phytocompounds; EGCg, Chlorogenic acid, Coumaroyl quinic acid and Rutin trihydrate along with a known antimycotic Fluconazole were studied for their antimycotic activity against Candida glabrata. The MIC90 for C. glabrata was observed at 125µg/ml for EGC g, 250 µg/mlf or Chlorogenic acid, 500µg/ml for Coumaroyl quinic acid and Rutin trihydrate while 12.5µg/ml for Fluconazole in macro dilution assay while the MFC values were 1000 µg/ml for EGC g, 500 µg/ml for Chlorogenic acid, Coumaroyl quinic acid, Rutin trihydrate and 50 µg/ml for Fluconazole. In microdilution assay, the MIC90 for C. glabrata was observed 125µg/ml for EGC g and chlorogenic acid, 500µg/ml for Coumaroyl quinic acid, Rutin trihydrate and 12.5µg/ml for Fluconazole while the MFC values were 31.25 µg/ml for Fluconazole, 250 µg/ml for chlorogenic acid and 500 µg/ml for EGC g, Coumaroyl quinic acid and Rutin trihydrate. EGCg and Chlorogenic acid was found to be more effective against C. glabrata and therefore these two were used for synergistic study along with Fluconazole. The viability of HeLa cells (in per cent) was observed ≥100% green tea phyto compounds. The viability of treated cells (in per cent) with a combination of Green tea, phytocompounds and fluconazole was observed between ≥98± 0.79 to ≥ 98± 0.87. Green tea phytocompounds mainly EGC g and chlorogenic acid can be used as synergistic molecules having antimycotic activity against C. glabrata.
How to Cite
Downloads
##plugins.themes.bootstrap3.article.details##
Antimycotic Activity, Candida glabrata, Green tea, phytocompounds, viability
Anand J, Rai N, Kumar N, Gautam P. (2012). Green tea: a magical herb with miraculous outcomes. Int. Res. J. Pharm. 3(5): 139-148.
Anand, J., & Rai, N. (2017). Anticandidal synergistic activity of green tea catechins, antimycotics and copper sulphate as a mean of combinational drug therapy against candidiasis. Journal de mycologie medicale, 27(1), 33–45.
Behbehani, J. M., Irshad, M., Shreaz, S., & Karched, M. (2019). Synergistic effects of tea polyphenol epigallocatechin 3-O-gallate and azole drugs against oral Candida isolates. Journal de mycologie medicale, 29(2), 158–167.
Cattaneo, L., Buonomo, A. R., Iacovazzo, C., Giaccone, A., Scotto, R., Viceconte, G., Mercinelli, S., Vargas, M., Roscetto, E., Cacciatore, F., Salvatore, P., Catania, M. R., Villari, R., Cittadini, A., Gentile, I., & Covid Federico Ii Team (2023). Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves. Journal of fungi (Basel, Switzerland), 9(1), 86.
Chew, S. Y., Ho, K. L., Cheah, Y. K., Sandai, D., Brown, A. J. P., & Than, L. T. L. (2019). Physiologically Relevant Alternative Carbon Sources Modulate Biofilm Formation, Cell Wall Architecture, and the Stress and Antifungal Resistance of Candida glabrata. International journal of molecular sciences, 20(13), 3172.
CLSI. (2002). M27-A2, Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-2nd Ed., vol.22, no.15.
Fadeyi, S. A., Fadeyi, O. O., Adejumo, A. A., Okoro, C., & Myles, E. L. (2013). In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC complementary and alternative medicine, 13, 79.
Gómez-Gaviria, M., Ramírez-Sotelo, U., & Mora-Montes, H. M. (2022). Non-albicans Candida Species: Immune Response, Evasion Mechanisms, and New Plant-Derived Alternative Therapies. Journal of fungi (Basel, Switzerland), 9(1), 11. https://doi.org/10.3390/jof9010011
Haghjoo, B., Lee, L.H., Habiba, U., Tahir, H., Olabi, M.M., & Chu, T. (2013). The synergistic effects of green tea polyphenols and antibiotics against potential pathogens. Advances in Bioscience and Biotechnology, 4, 959-967.
Haji, M.H., Mohamed, A.B., Albashir, A.A., & Mirghani, M.E. (2022). A Review of Antifungal Activity of Combined Plant Extracts or Plant Exudates from Medicinal Plants either together or with Known Antifungal Agents. European Journal of Medicinal Plants.
Hirasawa, M., & Takada, K. (2004). Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans. The Journal of antimicrobial chemotherapy, 53(2), 225–229.
Jin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X., & Yu, L. (2010). The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Letters in applied microbiology, 51(3), 351–357.https://doi.org/10.1111/j.1472-765X.2010.02900.x
Kane, A., & Carter, D. A. (2022). Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox. Pharmaceuticals (Basel, Switzerland), 15(4), 482.
Kaya, E.G., & Ozbilge, H. (2012). Determination of the effect of fluconazole against Candida albicans and Candida glabrata by using microbroth kinetic assay*. Turkish Journal of Medical Sciences.
Kováč, J., Slobodníková, L., Trajčíková, E., Rendeková, K., Mučaji, P., Sychrová, A., & Bittner Fialová, S. (2022). Therapeutic Potential of Flavonoids and Tannins in Management of Oral Infectious Diseases-A Review. Molecules (Basel, Switzerland), 28(1), 158.
Kumar, K., Askari, F., Sahu, M. S., & Kaur, R. (2019). Candida glabrata: A Lot More Than Meets the Eye. Microorganisms, 7(2), 39.
Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023). Immune responses to human fungal pathogens and therapeutic prospects. Nature reviews. Immunology, 23(7), 433–452. https://doi.org/10.1038/s41577-022-00826-w
Lu, M., Li, T., Wan, J., Li, X., Yuan, L., & Sun, S. (2017). Antifungal effects of phytocompounds on Candida species alone and in combination with fluconazole. International journal of antimicrobial agents, 49 2, 125-136.
Marchetti, O., Moreillon, P., Glauser, M.P., Billé, J., & Sanglard, D. (2000). Potent Synergism of the Combination of Fluconazole and Cyclosporine in Candida albicans. Antimicrobial Agents and Chemotherapy, 44, 2373 - 2381.
Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M.C. (2019). Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection. Microbial Cell, 6, 142 - 159.
Patel, LR., JD, Pethani., P, Bhatia., SD, Rathod., P.D, Shah. (2012). Prevalence of Candida infection and its antifungal susceptibility pattern in tertiary care hospital, Ahmedabad. Nat J Med Res. 2: 439-441.
Pfaller, M. A., Diekema, D. J., Procop, G. W., & Rinaldi, M. G. (2007). Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. Journal of clinical microbiology, 45(11), 3522–3528.
Radji, M., Agustama, R. A., Elya, B., & Tjampakasari, C. R. (2013). Antimicrobial activity of green tea extract against isolates of methicillin-resistant Staphylococcus aureus and multi-drug resistant Pseudomonas aeruginosa. Asian Pacific journal of tropical biomedicine, 3(8), 663–666. https://doi.org/10.1016/S2221-1691(13)60133-1
Singh, RI., I, Xess., P, Mathur., B, Behera., B, Gupta., M C, Misra. (2011). Epidemiology of candidaemia in critically ill trauma patients: experiences of a level I trauma centre in North India. J Med Microbiol. 60: 342-348.
Sirari, P., Anand, J., Devvret, Thapliyal, A & Rai, N. (2021). Green tea phytocompounds targets Lansterol 14-α demethylase against ergosterol biosynthesis in Candida glabrata. International Journal of Research in Pharmaceutical Sciences, 12(3), 1793–1797. Retrieved from https://ijrps.com/home/article/view/304
Yapar, N. (2014). Epidemiology and risk factors for invasive candidiasis. Therapeutics and clinical risk management, 10, 95–105.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
